Pharmacosmos A/S is delighted to announce that marketing approval has been granted for MonoferricTM (global brand name Monofer®) in Canada. MonoferricTM is approved for the treatment of iron deficiency anemia in adult patients who have intolerance or unresponsiveness to oral iron therapy. Monoferric will be available in Canada in November, 2018. In 2015 Pharmacosmos entered into an agreement with Pfizer Canada who have the exclusive commercialisation rights to MonoferricTM in Canada.
The structure of MonoferricTM is designed to be different from other intravenous iron replacement therapies, with a matrix structure of linear isomaltoside chains interspersed with Fe3+, allowing the possibility to administer high doses of iron, often in only one visit to the doctor, for the benefit and convenience of patients, healthcare professionals and hospital budgets.
Michael Ryde, VP Partners & Marketing at Pharmacosmos commented: “We are excited by the opportunity to introduce MonoferricTM in Canada (known as MONOFER® in other countries) with Pfizer as our partner. We believe that MonoferricTM will serve unmet clinical needs with a clear potential to improve outcomes and convenience for Canadian patients and we have great confidence in Pfizer to establish MonoferricTM as a leading IV iron brand in Canada.”
Cole Pinnow, General Manager, Pfizer Global Established Pharma Business in Canada, said: “We are pleased to be able to launch MonoferricTM in Canada later this year and believe strongly that this new treatment option reinforces Pfizer’s ongoing commitment to bringing innovative solutions to the lives of Canadian patients.”
For more information, please contact:
Vice President, Partners & Marketing
M: +45 26 48 74 16
T: +45 59 48 59 59
For media/external inquiries
Fonnesbech & Estrup
Tel: +45 28 74 87 10
Monoferric® (ferric derisomaltose, also known as iron isomaltoside 1000) is currently marketed, under different brand names, in over 30 countries worldwide including Canada, Australia and in the EU and has been studied in 25 clinical trials involving more than 5800 patients.
Iron deficiency anaemia (IDA) is a debilitating condition that affects almost 2 billion people worldwide 1. IDA is often associated with many chronic disorders such as renal diseases (including Chronic Kidney Disease), cancers (including chemotherapy-induced anaemia), gynaecologic disorders (including abnormal uterine bleeding) and inflammatory bowel disease (IBD).
Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.
Pharmacosmos has subsidiaries in US, China, UK, Ireland, Germany, Sweden and Norway and its products are marketed in more than 80 countries around the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world’s best known and most prescribed medicines, vaccines and consumer health products. Pfizer’s ongoing research and development activities focus on a wide range of therapeutic areas following our guiding aspiration: Working together for a healthier worldTM. To learn more about Pfizer Canada, visit pfizer.ca or you can follow us on Twitter (twitter.com/PfizerCA) or Facebook (facebook.com/Pfizer.Canada).
You are now leaving Pharmacosmos.com. The website you are about to visit is is a Pharmacosmos subsidary. Do you want to proceed?